An Aurinia Pharmaceuticals Inc. (AUPH) Director Buys 5000.0 Shares

0
23
Business man trader investor analyst using mobile phone app analytics for cryptocurrency financial stock market analysis analyze graph trading data index investment growth chart on smartphone screen.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) finished Wednesday with a subtraction of -$0.15 to close at $7.47, a downside of -1.97 percent. An average of 2,430,680 shares of common stock have been traded in the last five days. There was a fall of -$0.02 in the past week, and it reached a new high 8 times over the past 12 months. The last 20 days have seen an average of 2,142,520 shares traded, while the 50-day average volume stands at 2,517,572.

AUPH stock has decreased by -2.10% in the last month. The company shares reached their 1-month lowest point of $6.28 on 09/08/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $6.28 and a high of $33.97 in 52 weeks. It has reached a new high 1 time so far this year and lost -67.34% or -$15.40 in price. In spite of this, the price is down -78.01% from the 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Insider Transactions

204 days have passed since Aurinia Pharmaceuticals Inc. (AUPH) last reported insider trading activity. Donley Matthew Maxwell, who is Ex VP, Intern’l Operations, most recently acquired $3,052 shares at $12.01 per share on Mar 02. In this transaction, the insider spent $36,655. Chief Business Officer, Martin Michael Robert, disposed of 4,849 shares at a price of $12.01 on Mar 02. The insider now owns more than $58,236 worth of shares. Prior to that, EVP of Research Huizinga Robert Bindert went on to Sale 4,849 shares at $12.01 each on Mar 02. An amount of $58,236 was transacted.

Valuation Metrics

Aurinia Pharmaceuticals Inc. (AUPH) stock’s beta is 0.97. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 12.52, the price-to-book (PB) ratio at 2.50.

Financial Health

The quick ratio of Aurinia Pharmaceuticals Inc. for the three months ended June 29 was 12.30, and the current ratio was 13.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $44.51 million compared to revenue of $45.6 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Aurinia Pharmaceuticals Inc.’s return on assets was -33.10%.

Earnings Surprise

In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$35.52 million in the quarter, while revenues of -$37.63 million were shrunk -32.35%. The analyst consensus anticipated Aurinia Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.22 per share, but it turned out to be -$0.25, a -13.60% surprise. For the quarter, EBITDA amounted to -$35.47 million. Shareholders own equity worth $141.89 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Aurinia Pharmaceuticals Inc. (AUPH) price momentum. RSI 9-day as of the close on 21 September was 48.78%, suggesting the stock is Neutral, with historical volatility in this time frame at 44.95%.

As of today, AUPH’s price is $7.52 -0.27% or -$0.02 from its 5-day moving average. AUPH is currently trading -5.68% lower than its 20-day SMA and -28.99% lower than its 100-day SMA. However, the stock’s current price level is -36.91% below the SMA50 and -59.99% below the SMA200.

The stochastic %K and %D were 83.66% and 79.87%, respectively, and the average true range (ATR) was 0.42. With the 14-day stochastic at 76.77% and the average true range at 0.45, the RSI (14) stands at 44.93%. The stock has reached 0.11 on the 9-day MACD Oscillator while the 14-day reading was at 0.29.

Analyst Ratings

The consensus rating for Aurinia Pharmaceuticals Inc. (AUPH) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell AUPH, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 7 others rate it as a “buy”.

What is AUPH’s price target for the next 12 months?

Analysts predict a range of price targets between $13.00 and $30.00, with a median target of $21.50. Taking a look at these predictions, the average price target given by analysts for Aurinia Pharmaceuticals Inc. (AUPH) stock is $21.31.

LEAVE A REPLY

Please enter your comment!
Please enter your name here